Literature DB >> 760754

Serum, tear and salivary concentrations of methotrexate in man.

W H Steele, J F Stuart, B Whiting, J R Lawrence, K C Calman, J G McVie, G M Baird.   

Abstract

1. Methotrexate handling has been studied in four patients with psoriasis and eleven patients with neoplastic disease. 2. Methotrexate levels in serum, tears and saliva were measured by radioimmunoassay while protein binding studies were performed by continuous ultrafiltration. 3. There was a close correlation between methotrexate concentrations in tears and serum (P less than 0.001, r = 0.714). Parotid salivary and serum methotrexate levels were similarly correlated (P less than 0.001, r = 0.557) but not mixed salivary and serum levels (P greater than 0.1, r = 0.232). 4. The mean protein binding was 95.11% +/- 2.26 (s.d.) while the ratio of methotrexate levels in tears to the free serum methotrexate level was 1:1.04. The corresponding parotid salivary level: free serum level ratio was 1:18.11. 5. No relationship could be determined between the methotrexate levels in tears and conjunctivitis observed in some of the patients under study.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760754      PMCID: PMC1429434          DOI: 10.1111/j.1365-2125.1979.tb00923.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  PARENTERAL METHOTREXATE IN PSORIASIS.

Authors:  E J VANSCOTT; R AUERBACH; G D WEINSTEIN
Journal:  Arch Dermatol       Date:  1964-04

2.  Estimation of the antileukemic potency of the antimetabolite aminopterin, administered alone and in combination with citrovorum factor or folic acid.

Authors:  A GOLDIN; N MANTEL; S W GREENHOUSE; J M VENDITTI; S R HUMPHREYS
Journal:  Cancer Res       Date:  1953-12       Impact factor: 12.701

3.  Effect of aminopterin on epithelial tissues.

Authors:  R GUBNER
Journal:  AMA Arch Derm Syphilol       Date:  1951-12

4.  Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology.

Authors:  K W Stephen; C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

5.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

6.  Treatment of psoriasis with minute divided oral doses of methotrexate.

Authors:  J M Spiro; D J Demis
Journal:  Arch Dermatol       Date:  1969-04

7.  Measurement of drug displacement by continuous ultrafiltration.

Authors:  D S Campion; R Olsen
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

8.  A rapid, sensitive and specific radioimmunoassay for methotrexate.

Authors:  J W Paxton; F J Rowell
Journal:  Clin Chim Acta       Date:  1977-11-01       Impact factor: 3.786

9.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

10.  Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding.

Authors:  J R Taylor; K M Halprin
Journal:  Arch Dermatol       Date:  1977-05
View more
  3 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.

Authors:  H Schrøder; K B Jensen; M Brandsborg
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.